Drug Profile

Clobetasol propionate - Promius Pharma

Alternative Names: DFD 06; Impoyz

Latest Information Update: 09 Dec 2021

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Promius Pharma
Developer Encore Dermatology; Promius Pharma
Class Anti-inflammatories; Antipsoriatics; Antiulcers; Fluorinated steroids; Glucocorticoids; Halogenated hydrocarbons; Propionates
Mechanism of Action Steroid receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Plaque psoriasis

Most Recent Events

03 Jun 2020 Encore Dermatology terminates phase II trial in Plaque psoriasis (In children, In adolescents) in USA due to difficulty in enrollment (Topical) (NCT03179605)
01 May 2018 Launched for Plaque psoriasis (In adults) in USA (Topical)
06 Dec 2017 Chemical structure information added

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com